PMP 2207
Alternative Names: PMP-2207Latest Information Update: 26 Jul 2022
At a glance
- Originator Novartis Pharma A.G.
- Developer Premark Pharma
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Cytokine inhibitors; Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Blepharitis
Highest Development Phases
- Phase III Blepharitis
Most Recent Events
- 26 Jul 2022 Phase-III clinical trials in Blepharitis in Switzerland (Ophthalmic) before July 2022 (Premark Pharma website, July 2022)
- 26 Jul 2022 Premark pharma completes a phase II clinical trial in Blepharitis in Switzerland (Ophthalmic) before July 2022 (Premark pharma website, July 2022)
- 25 Jun 2019 PMP 2207 is available for licensing as of 25 Jun 2019. https://www.premarkpharma.com/